In Brief: Lilly Evista
Executive Summary
Lilly Evista: FDA's Endocrinologic & Metabolic Drugs Advisory Committee will review NDA 20-815 for raloxifene for prevention of osteoporosis in postmenopausal women on Nov. 20. Meeting will begin at 8 a.m. at the Holiday Inn in Bethesda, Md...